Shareholder Information
On 19 November 2012, Amsterdam Molecular Therapeutics (AMT) Holding N.V. delisted from NYSE Euronext in Amsterdam and the company and its shares ceased to exist.
|
Extraordinary Annual General Meeting 2012 Amsterdam Molecular Therapeutics (AMT) Holding N.V. (in liquidation) Provides Publication of the minutes of the Extraordinary Annual General Meeting held on 30th March 2012. |
|
Annual General Meeting 2012 Amsterdam Molecular Therapeutics (AMT) Holding N.V. (in liquidation) Announces Publication of its Accounts for 2011 and Notice of Annual General Meeting. Amsterdam, The Netherlands – July 13, 2012 – Amsterdam Molecular Therapeutics (AMT) Holding NV (in liquidation) (Euronext: AMT) published its Annual Report and Accounts for the year ended December 31, 2011 and announced that it will host its Annual General Meeting at its headquarters (Meibergdreef 61, 1105 BA Amsterdam Zuidoost, the Netherlands) at 14.00 hrs on September 12, 2012. Shareholders of the dissolved company are invited to attend. Press release EN |
|
Notice to holders of Depositary Receipts of ordinary shares B in uniQure B.V. issued by Stichting Administratiekantoor uniQure B.V. (ISIN NL 0010124913) Bericht aan houders van certificaten van aandelen B in uniQure B.V. uitgegeven door Stichting Administratiekantoor uniQure B.V. (ISIN NL0010124913) Download Notice En |
|
Overview of key transaction elements and timetable with regard to the public-to-private and financing transaction between Click here to download PDF |
|
Explanatory note to Constitutional Documents |
|
|
|
Amsterdam Molecular Therapeutics Summary and Q&A of the Shareholder Information Meetings on 23 February and 20 March, 2012 |
|
Proxy and Instruction to Vote for the EGM to be held on A shareholder who chooses to have himself represented at the Extraordinary General Meeting by a third party must provide AMT with a proxy to that effect. For the granting of a proxy, shareholders are required to use the form, which can be obtained here or via Aicha Diba, telephone number: +31 (0)20 5668014; telefax number: +31 (0)20 5669272. The completed form, duly completed by the shareholder, must have been received by AMT by 15:00 CET on 27 March 2012 ultimately. Receipt of proxy forms can be rejected after this time deadline. Participation in the meeting can be made dependant on identification of the participants. |
|
Shareholder Information Meeting 20 March 2012 In conjunction with the announcement on Friday February 17, 2012 of AMT’s Business being acquired by uniQure BV, we are pleased to invite you to our company on March 20, 2012 from 17.00 – 19.00 at AMT, 61 Meibergdreef in Amsterdam for an informational meeting on the transaction. During this meeting, Ferdinand Verdonck head of the Special Committee for the evaluation of the transaction, Jörn Aldag (CEO), Piers Morgan (CFO) Dr. Carlos Camozzi (Chief Medical Officer) will be on hand to answer investor questions. You can sign up for this meeting by sending an e-mail to amtir@amtbiopharma.com For this meeting we have a maximum capacity of 30 people, so if you want to attend this meeting, it is necessary to register a.s.a.p. For questions or more information please contact Aicha Diba on the aforementioned e-mail or telephone +31 20 566 80 14.
Naar aanleiding van de op 17 februari aangekondigde acquisitie door uniQure BV van AMT, nodigen wij u graag uit voor een informatieve bijeenkomst op 20 maart a.s. van 17.00 – 19.00 uur bij AMT aan de Meibergdreef 61 te Amsterdam. Tijdens deze bijeenkomst zullen Ferdinand Verdonck, voorzitter van het Speciale Comité , Jörn Aldag (CEO), Piers Morgan (CFO), Dr. Carlos Camozzi (Chief Medical Officer) na een korte presentatie vragen van investeerders beantwoorden. U kunt zich voor deze bijeenkomst aanmelden door een e-mail te sturen naar amtir@amtbiopharma.comEr zijn voor deze bijeenkomst maximaal 30 plaatsen beschikbaar. Indien u bij deze meeting aanwezig wilt zijn is het dus noodzakelijk uzelf tijdig in te schrijven. Voor vragen of meer informatie kunt u contact opnemen met Aicha Diba via eerder genoemd e-mailadres of telefoonnummer 020 - 566 80 14 |
|
Shareholder Information Meeting 23 February 2012 The presentation is available to download here The minutes of the shareholder information meeting are available to download here |
|
|
|
Amsterdam Molecular Therapeutics Business to be Acquired by uniQure BV Amsterdam, The Netherlands – February 17, 2012 – Amsterdam Molecular Therapeutics (Euronext: AMT) announced today that its board of directors is recommending a substantial corporate restructuring and financing transaction which, if approved by shareholders, will result in the assets and certain liabilities being acquired by a newly formed private company, uniQure BV, and the AMT legal entity being liquidated and delisted. Extraordinary Shareholder Meeting called to vote on the Transaction. Notice of EGM |
|
Annual General Meeting 2011 Organized by Amsterdam Molecular Therapeutics (AMT) Holding N.V., having its address at Meibergdreef 61, 1105 BA Amsterdam Zuidoost, the Netherlands, on May 3, 2011, at 14.00 hours. On the date of the notice for this meeting, the company had 23,512,225 shares issued, each representing one vote. AGM Notice |
|
October 2010 Private Placement Information October 5, 2010 Not for release, publication or distribution in whole or in part, directly or indirectly, in or into the United States, Australia, Canada, Japan or South Africa or to US persons. This announcement is not a prospectus and is not an offer for sale of securities in the United States, Canada, South Africa, Australia, Japan or any other jurisdiction. Amsterdam Molecular Therapeutics (AMT) Holding N.V. (Euronext: AMT) announces October 5, 2010 the launch of an equity offering by means of a private placement. Underneath the prospectus, press releases and other relevant information. Press Release, Result of the Equity Offering |
Financial Calendar 2011
Q1 Business Update
May 19, 2011
Half Year Results
August 25, 2011
Q3 Business Update
November 17, 2011
Full Year Results 2011
April 26, 2012